Issuance of Final Guidance Publications, 20606 [2017-08887]
Download as PDF
20606
Federal Register / Vol. 82, No. 84 / Wednesday, May 3, 2017 / Notices
1. Piedmont Bancorp, Inc., Norcross,
Georgia; to merge with Mountain Valley
Bancshares, Inc., and thereby indirectly
acquire, Mountain Valley Community
Bank, both of Cleveland, Georgia.
B. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President), 230 South LaSalle Street,
Chicago, Illinois 60690–1414:
1. West Town Bancorp, Inc., Raleigh,
North Carolina; to acquire 100 percent
of the outstanding voting shares of
Sound Banking Company, Morehead
City, North Carolina.
Board of Governors of the Federal Reserve
System, April 27, 2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2017–08890 Filed 5–2–17; 8:45 am]
Trust Company, LLC. Plimoth
Massachusetts, and thereby engage in
trust company activities pursuant to
section 225.28(b)(5).
In addition, Plimoth has applied to
acquire certain assets and assume
certain liabilities from Savings Institute
Bank and Trust Company, Willimantic,
Connecticut.
Dated: April 27, 2017.
Frank Hearl,
Chief of Staff, National Institute for
Occupational Safety and Health, Centers for
Disease Control and Prevention.
Board of Governors of the Federal Reserve
System, April 27, 2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–08854 Filed 5–2–17; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 6210–01–P
Centers for Disease Control and
Prevention
FEDERAL RESERVE SYSTEM
[CDC–2015–0021; Docket Number NIOSH–
153–C]
nlaroche on DSK30NT082PROD with NOTICES
Notice of Proposals To Engage in or
To Acquire Companies Engaged in
Permissible Nonbanking Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y, (12
CFR part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than May 17, 2017.
A. Federal Reserve Bank of Boston
(Prabal Chakrabarti, Senior Vice
President) 600 Atlantic Avenue, Boston,
Massachusetts 02210–2204. Comments
can also be sent electronically to
BOS.SRC.Applications.Comments@
bos.frb.org:
1. Narragansett Financial Corp.,
Swansea, Massachusetts; to retain 80
percent of the voting shares of Plimoth
VerDate Sep<11>2014
14:29 May 02, 2017
Jkt 241001
Issuance of Final Guidance
Publications
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of issuance of final
guidance publications.
AGENCY:
NIOSH announces the
availability of the following final 5 Skin
Notation Profiles: Acrylic acid [CAS No.
79–01–7], Dichlorvos [CAS No. 62–73–
7], Morpholine [CAS No. 110–91–8],
Ethyl p-nitrophenyl
phenylphosphorothioate (EPN) [CAS
No. 2104–64–5], Dioxathion [CAS No.
78–34–2].
DATES: The final Skin Notation Profiles
documents were published on April 10,
2017.
ADDRESSES: These documents may be
obtained at the following link: https://
www.cdc.gov/niosh/topics/skin/skinnotation_profiles.html.
FOR FURTHER INFORMATION CONTACT:
Naomi Hudson, Dr. P.H., NIOSH,
Education and Information Division
(EID), Robert A. Taft Laboratories, 1090
Tusculum Ave. MS–C32, Cincinnati,
OH 45226, email: iuz8@cdc.gov.
SUPPLEMENTARY INFORMATION: On May 1,
2015, NIOSH published a request for
public review in the Federal Register
[80 FR 24932] on skin notation profiles
and technical documents. All comments
received were reviewed and accepted
where appropriate.
SUMMARY:
PO 00000
Frm 00048
Fmt 4703
Sfmt 9990
[FR Doc. 2017–08887 Filed 5–2–17; 8:45 am]
BILLING CODE 4163–19–P
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Peer Review Meeting.
Date: June 1, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, Room
3F40, 5601 Fishers Lane, Rockville, MD
20892 (Telephone Conference Call).
Contact Person: Robert C. Unfer, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 5601
Fishers Lane, Room 3F40 MSC 9823,
Rockville, MD 20892–9823, 240–669–5035,
unferrc@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 28, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–08946 Filed 5–2–17; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\03MYN1.SGM
03MYN1
Agencies
[Federal Register Volume 82, Number 84 (Wednesday, May 3, 2017)]
[Notices]
[Page 20606]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08887]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[CDC-2015-0021; Docket Number NIOSH-153-C]
Issuance of Final Guidance Publications
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of issuance of final guidance publications.
-----------------------------------------------------------------------
SUMMARY: NIOSH announces the availability of the following final 5 Skin
Notation Profiles: Acrylic acid [CAS No. 79-01-7], Dichlorvos [CAS No.
62-73-7], Morpholine [CAS No. 110-91-8], Ethyl p-nitrophenyl
phenylphosphorothioate (EPN) [CAS No. 2104-64-5], Dioxathion [CAS No.
78-34-2].
DATES: The final Skin Notation Profiles documents were published on
April 10, 2017.
ADDRESSES: These documents may be obtained at the following link:
https://www.cdc.gov/niosh/topics/skin/skin-notation_profiles.html.
FOR FURTHER INFORMATION CONTACT: Naomi Hudson, Dr. P.H., NIOSH,
Education and Information Division (EID), Robert A. Taft Laboratories,
1090 Tusculum Ave. MS-C32, Cincinnati, OH 45226, email: iuz8@cdc.gov.
SUPPLEMENTARY INFORMATION: On May 1, 2015, NIOSH published a request
for public review in the Federal Register [80 FR 24932] on skin
notation profiles and technical documents. All comments received were
reviewed and accepted where appropriate.
Dated: April 27, 2017.
Frank Hearl,
Chief of Staff, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2017-08887 Filed 5-2-17; 8:45 am]
BILLING CODE 4163-19-P